Person: TÜRK, HACI MEHMET
19 results
Search Results
Now showing 1 - 10 of 19
Publication Open Access Multiple myeloma mimicking metastatic lung cancer(2015-01-01) Furuncuoglu, Yavuz; Cirak, Yalcin; Turk, HACI MEHMET; BASAR, Melih; Ortapamuk, Hulya; KAUR, Ahmet Cemil; TÜRK, HACI MEHMETMultiple myeloma is a hematological malignancy characterized by a clonal proliferation of plasma cells in the bone marrow. Extramedullary dissemination of multiple myeloma is uncommon. Only in rare cases, the malignant plasma cells of multiple myeloma had infiltrated the lung parenchyma. In this case report, we presented a case of multiple myeloma with lung plasmacytoma, in a 42-year-old patient, hospitalized for pain and infiltrative mass in the right lung. The results of his initial evaluation with computed tomography and positron emission tomograpy scanning, resembled lung tumor with bone metastasis. Surprisingly, biopsies from lung tumor and bone metastasis, revealed malignant plasma cells. We found M spike in protein electrophoresis and lambda monoclonal band in immune electrophoresis. A bone marrow biopsy evaluation was done and justified multiple myeloma diagnosis before hematology referral. Multiple myeloma diagnosis at the age of 42 is quite rare.Publication Metadata only F-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (F-18-FDG PET/CT) Maximum Standardized Uptake Value (SUVmax) as a Prognostic Factor in Non-Hodgkin Lymphoma Patients(2013-10-01) Adli, M.; Caglayan, D.; Koc, M.; Zincirkeser, S.; Turk, HACI MEHMET; TÜRK, HACI MEHMETPublication Metadata only An unusual presentation of extramedullary plasmacytoma in testis and review of the literature.(2010-12-01T00:00:00Z) Turk, HACI MEHMET; KOMURCU, S; OZET, A; KUZHAN, O; GÜNHAN, O; TÜRK, HACI MEHMETPublication Metadata only Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting?(2021-08-01T00:00:00Z) Besiroglu, Mehmet; Demir, Tarik; Shbair, Abdallah T M; Yasin, Ayse Irem; Topcu, Atakan; Turk, HACI MEHMET; TÜRK, HACI MEHMETPublication Metadata only Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.(2022-10-13T00:00:00Z) Wainberg, Zev A; Enzinger, Peter C; Kang, Yoon-Koo; Qin, Shukui; Yamaguchi, Kensei; Kim, In-Ho; Saeed, Anwaar; Oh, Sang Cheul; Li, Jin; Turk, HACI MEHMET; Teixeira, Alexandra; Borg, Christophe; Hitre, Erika; Udrea, Adrian A; Cardellino, Giovanni Gerardo; Sanchez, Raquel Guardeño; Collins, Helen; Mitra, Siddhartha; Yang, Yingsi; Catenacci, Daniel V T; Lee, Keun-Wook; TÜRK, HACI MEHMETMagnetic monopoles are known to emerge as leading non-perturbative fluctuations in the lattice version of non-Abelian gauge theories in some gauges. In terms of the Dirac quantization condition, these monopoles have magnetic charge |Q_M|=2. Also, magnetic monopoles with |Q_M|=1 can be introduced on the lattice via the -t Hooft loop operator. We consider the |Q_M|=1,2 monopoles in the continuum limit of the lattice gauge theories. To substitute for the Dirac strings which cost no action on the lattice, we allow for singular gauge potentials which are absent in the standard continuum version. Once the Dirac strings are allowed, it turns possible to find a solution with zero action for a monopole--antimonopole pair. This implies equivalence of the standard and modified continuum versions in perturbation theory. To imitate the nonperturbative vacuum, we introduce then a nonsingular background. The modified continuum version of the gluodynamics allows in this case for monopoles with finite non-vanishing action. Using similar techniques, we construct the -t Hooft loop operator in the continuum and predict its behavior at small and large distances both at zero and high temperatures.Publication Metadata only Isolated renal relapse of a case with non-Hodgkin-s lymphoma.(2010-06-01T00:00:00Z) Turk, HACI MEHMET; OZET, A; OZTURK, M; KOMURCU, S; KUZHAN, O; ARPACI, F; OZTURK, B; SAFALI, M; TÜRK, HACI MEHMETPublication Metadata only Cyclooxygenase-2 expression is not a marker of poor survival in lung cancer.(2012-01-01T00:00:00Z) Turk, HACI MEHMET; CAMCI, C; SEVINC, A; BUKYUKBERBER, S; SARI, I; ADLI, M; TÜRK, HACI MEHMETPublication Metadata only Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.(2021-02-13T00:00:00Z) Sezer, Ahmet; Kilickap, Saadettin; Gümüş, Mahmut; Bondarenko, Igor; Özgüroğlu, Mustafa; Gogishvili, Miranda; Turk, HACI MEHMET; Cicin, Irfan; Bentsion, Dmitry; Gladkov, Oleg; Clingan, Philip; Sriuranpong, Virote; Rizvi, Naiyer; Gao, Bo; Li, Siyu; Lee, Sue; McGuire, Kristina; Chen, Chieh-I; Makharadze, Tamta; Paydas, Semra; Nechaeva, Marina; Seebach, Frank; Weinreich, David M; Yancopoulos, George D; Gullo, Giuseppe; Lowy, Israel; Rietschel, Petra; TÜRK, HACI MEHMETPublication Metadata only Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer.(2021-07-29T00:00:00Z) Topcu, Atakan; Atci, Muhammed Mustafa; Secmeler, Saban; Besiroglu, Mehmet; Ayhan, Murat; Ozkan, Metin; Bozkurt, Oktay; Urakci, Zuhat; Ay, Seval; Geredeli, Caglayan; Yasin, Ayse Irem; Turk, HACI MEHMET; TÜRK, HACI MEHMETPublication Open Access Synchronous Hepatocellular Carcinoma and Cholangiocellular Carcinoma on F-18-FDG PET/CT(2018-10-01) Erdogan, EZGİ BAŞAK; Turk, HACI MEHMET; Tekce, ERTUĞRUL; Aydin, MEHMET; ERDOĞAN, EZGİ BAŞAK; TÜRK, HACI MEHMET; AYDIN, MEHMETA 43-year-old male patient presented with a mass lesion on the right liver lobe, segment 5, in radiological imaging and elevated alpha-fetoprotein levels (323 ng/mL) compatible with hepatocellular carcinoma (HCC). Positron emission tomography/computed tomography (PET/CT) images showed background level 18F-FDG uptake in the mass lesion. In addition, a secondary focus of increased 18F-FDG uptake was detected on the left liver lobe, segment 2, approximately 1,5 cm in diameter. Histopathological examination revealed HCC in the larger mass lesion with a lower 18F-FDG uptake, and cholangiocellular carcinoma in the smaller mass lesion with a higher 18F-FDG uptake. To our knowledge, this is the first case report of two histopathologically different primary malignant liver tumors in two distinct segments of the liver detected by PET/CT.